Overview Dividends

(NUVB) Nuvation Bio - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US67080N1019

Oncology Pipeline Drug Candidates

NUVB EPS (Earnings per Share)

EPS Growth (3Y CAGR): -42.17%
EPS Trend (3Y Correlation): -72.4%

NUVB Revenue

Revenue Growth (3Y CAGR): 661.46%
Revenue Trend (3Y Correlation): 91.0%

Risk via 10d forecast
Volatility	81.4%
Value at Risk 5%th	117%

Reward
Sharpe Ratio	1.03
Alpha Jensen	66.45

Character
Hurst Exponent	0.400
Beta	1.637

Drawdowns 3y
Max DD	61.13%
Mean DD	30.17%

Description: NUVB Nuvation Bio August 28, 2025

Nuvation Bio (NUVB) is a U.S.-based biotech firm concentrating on the development of novel therapeutics for rare diseases, leveraging proprietary gene‑editing and protein‑modulation platforms. The company’s strategic focus is on advancing a pipeline of pre‑clinical and early‑stage clinical candidates targeting high‑unmet‑need indications, positioning it to capture niche market share if regulatory milestones are achieved.

Financially, the firm operates with a market capitalization under $1 billion and exhibits negative equity returns, reflecting substantial R&D outlays relative to revenue. Cash balances are modest, resulting in a burn rate that necessitates periodic equity raises or partnership financing. The balance sheet shows limited debt, indicating reliance on equity markets for capital. Gross margin is not applicable due to the pre‑revenue nature of the business, and operating expenses are dominated by research, clinical trial costs, and administrative overhead.

The primary economic drivers are milestone payments and licensing revenues from collaborations with larger pharmaceutical partners, as well as potential product commercialization upon successful FDA approval. The pipeline includes at least two candidates in IND‑enabling studies, each targeting orphan indications with market sizes estimated in the low‑hundreds of millions. Successful trial outcomes would unlock significant upside through out‑licensing or direct market entry, while also enhancing the company’s credibility for future financing.

External factors influencing valuation include the biotech sector’s capital environment, regulatory risk, and competitive pressure from other firms pursuing similar mechanisms of action. Market sentiment is sensitive to trial data releases and partnership announcements; any delay or negative result can materially depress share price, whereas positive data can trigger rapid re‑rating by analysts.

NUVB Stock Overview

Market Cap in USD	1,622m
Sub-Industry	Biotechnology
IPO / Inception	2020-08-24
Return 12m vs S&P 500	43.3%
Analyst Rating	4.57 of 5

NUVB Dividends

Currently no dividends paid

NUVB Growth Ratios

CAGR	37.81%
CAGR/Max DD Calmar Ratio	0.62
CAGR/Mean DD Pain Ratio	1.25
Current Volume	4863.1k
Average Volume	7824.8k

Piotroski VR‑10 (Strict, 0-10) 1.0

Net Income (-217.5m TTM) > 0 and > 6% of Revenue (6% = 1.60m TTM)

FCFTA -0.32 (>2.0%) and ΔFCFTA -14.25pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 1904 % (prev 18.8k%; Δ -16.9kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA -0.32 (>3.0%) and CFO -190.0m > Net Income -217.5m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 8.48 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (342.4m) change vs 12m ago 25.16% (target <= -2.0% for YES)

Gross Margin 54.26% (prev -10.59%; Δ 64.85pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 4.56% (prev 0.47%; Δ 4.09pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -204.3 (EBITDA TTM -216.1m / Interest Expense TTM 1.06m) >= 6 (WARN >= 3)

Altman Z'' -1.54

(A) 0.85 = (Total Current Assets 577.5m - Total Current Liabilities 68.1m) / Total Assets 601.6m

(B) -1.79 = Retained Earnings (Balance) -1.08b / Total Assets 601.6m

warn (B) unusual magnitude: -1.79 — check mapping/units

(D) 1.18 = Book Value of Equity 325.9m / Total Liabilities 275.7m

Total Rating: -1.54 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 34.08

1. Piotroski 1.0pt = -4.0

2. FCF Yield -17.57% = -5.0

3. FCF Margin data missing

4. Debt/Equity 0.03 = 2.50

5. Debt/Ebitda 0.41 = 2.37

6. ROIC - WACC (= -61.42)% = -12.50

7. RoE -54.99% = -2.50

8. Rev. Trend 91.01% = 6.83

9. EPS Trend -72.38% = -3.62

What is the price of NUVB shares?

As of November 12, 2025, the stock is trading at USD 4.98 with a total of 4,863,077 shares traded.
Over the past week, the price has changed by +3.11%, over one month by +35.33%, over three months by +122.32% and over the past year by +65.45%.

Is Nuvation Bio a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Nuvation Bio (NYSE:NUVB) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 34.08 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of NUVB is around 4.37 USD . This means that NUVB is currently overvalued and has a potential downside of -12.25%.

Is NUVB a buy, sell or hold?

Nuvation Bio has received a consensus analysts rating of 4.57. Therefore, it is recommended to buy NUVB.

Strong Buy: 4
Buy: 3
Hold: 0
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the NUVB price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	8.7	74.1%
Analysts Target Price	8.7	74.1%
ValueRay Target Price	5	1%

NUVB Fundamental Data Overview November 10, 2025

Market Cap USD = 1.62b (1.62b USD * 1.0 USD.USD)
P/S = 60.6252
P/B = 3.4052
Beta = 1.637
Revenue TTM = 26.7m USD
EBIT TTM = -217.6m USD
EBITDA TTM = -216.1m USD
Long Term Debt = 47.0m USD (from longTermDebt, two quarters ago)
Short Term Debt = 7.49m USD (from shortTermDebt, last quarter)
Debt = 10.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -88.4m USD (from netDebt column, last quarter)
Enterprise Value = 1.08b USD (1.62b + Debt 10.5m - CCE 549.0m)
Interest Coverage Ratio = -204.3 (Ebit TTM -217.6m / Interest Expense TTM 1.06m)
FCF Yield = -17.57% (FCF TTM -190.2m / Enterprise Value 1.08b)
FCF Margin = -711.3% (FCF TTM -190.2m / Revenue TTM 26.7m)
Net Margin = -813.1% (Net Income TTM -217.5m / Revenue TTM 26.7m)
Gross Margin = 54.26% ((Revenue TTM 26.7m - Cost of Revenue TTM 12.2m) / Revenue TTM)
Gross Margin QoQ = 74.47% (prev 46.70%)
Tobins Q-Ratio = 1.80 (Enterprise Value 1.08b / Total Assets 601.6m)
Interest Expense / Debt = 4.79% (Interest Expense 501.0k / Debt 10.5m)
Taxrate = -0.0% (0.0 / -567.9m)
NOPAT = -217.6m (EBIT -217.6m * (1 - -0.00%)) [loss with tax shield]
Current Ratio = 8.48 (Total Current Assets 577.5m / Total Current Liabilities 68.1m)
Debt / Equity = 0.03 (Debt 10.5m / totalStockholderEquity, last quarter 325.9m)
Debt / EBITDA = 0.41 (negative EBITDA) (Net Debt -88.4m / EBITDA -216.1m)
Debt / FCF = 0.46 (negative FCF - burning cash) (Net Debt -88.4m / FCF TTM -190.2m)
Total Stockholder Equity = 395.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -36.15% (Net Income -217.5m / Total Assets 601.6m)
RoE = -54.99% (Net Income TTM -217.5m / Total Stockholder Equity 395.5m)
RoCE = -49.17% (EBIT -217.6m / Capital Employed (Equity 395.5m + L.T.Debt 47.0m))
RoIC = -49.42% (negative operating profit) (NOPAT -217.6m / Invested Capital 440.2m)
WACC = 12.00% (E(1.62b)/V(1.63b) * Re(12.05%) + D(10.5m)/V(1.63b) * Rd(4.79%) * (1-Tc(-0.0)))
Discount Rate = 12.05% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 25.06%
Fair Price DCF = unknown (Cash Flow -190.2m)
EPS Correlation: -72.38 | EPS CAGR: -42.17% | SUE: 0.15 | # QB: 0
Revenue Correlation: 91.01 | Revenue CAGR: 661.5% | SUE: 2.88 | # QB: 7

Additional Sources for NUVB Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle